| ID | 1099 |
| Name of the vaccine | Diphtheria and Tetanus Toxoids Adsorbed |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Toxoid |
| Nucleic acid content | DNA |
| Age | 6 weeks to 6 years |
| Description of the vaccine | Vaccine for diphtheria and tetanus. |
| Name of the manufacturer | Sanofi Pasteur Ltd |
| Name of the manufacturing country | Canada |
| Year of manufacture | 1997 |
| Clinical Phase status | Approved |
| Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
| Efficacy | Protective diphtheria and tetanus antitoxin levels developed in 100% of the recipients. |
| Vaccine formulation | Suspension for injection |
| Dosage | Five doses at at 2, 4, 6, 15-18 months and between 4 and 6 years. |
| Mechanism of action | Serum tetanus antitoxin level of 0.01 IU/mL is minimum protective level. |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria and tetanus. |
| Export | Distributed by: Sanofi Pasteur Inc., USA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For diphtheria also. |
| Side effects of vaccine | Crying, redness, swelling, tenderness, fever, moderate or severe arm mobility and loss of appetite. |
| Post vaccination | NA |
| Dose type | Combination (5 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/75962/download |
| Other name | NA |
| Additional Links | NA
|